Dose-response characteristics of uterine responses in rats exposed to estrogen agonists

Regulatory Toxicology and Pharmacology

Volumn 28, Issue 2, 1998, Pages 133-149

  Barton, Hugh A ^a   Andersen, Melvin E ^a   Allen, Bruce C ^a  

^a KS Crump Group   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTRADIOL;

ANALYTIC METHOD; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL PROLIFERATION; DOSE RESPONSE; DRUG EFFECT; DRUG RECEPTOR BINDING; DRUG REEXPOSURE; DRUG SCREENING; FEMALE; NONHUMAN; PRIORITY JOURNAL; RAT; TOXICITY TESTING; UTERUS WEIGHT; WATER RETENTION;

ANIMALIA;

EID: 0032459877     PISSN: 02732300     EISSN: None     Source Type: Journal    
DOI: 10.1006/rtph.1998.1244     Document Type: Article

References (50)

1. Altucci L., Addeo R., Cicatiello L., Germano D., Pacilio C., Battista T., Cancemi M., Petrizzi V. B., Bresciani F., Weisz A. Estrogen induces early and timed activation of cyclin-dependent kinases 4, 5, and 6 and increases cyclin messenger ribonucleic acid expression in rat uterus. Endocrinology. 138:1997;978-984.
2. Anderson J. N., Clark J. H., Peck E. J. Jr. The relationship between nuclear receptor-estrogen binding and uterotrophic responses. Biochem. Biophys. Res. Commun. 48:1972;1460-1468.
3. Anderson J. N., Peck E. J. Jr., Clark J. H. Nuclear receptor-estrogen complex: Relationship between concentration and early uterotrophic responses. Endocrinology. 92:1973;1488-1495.
4. Anderson J. N., Peck E. J. Jr., Clark J. H. Estrogen-induced uterine responses and growth: Relationship to receptor estrogen binding by uterine nuclei. Endocrinology. 96:1975;160-167.
5. Barlow R. B. Quantitative Aspects of Chemical Pharmacology. 1980;Univ. Park Press, Baltimore.
6. Barnes D. G., Daston G. P., Evans J. S., Jarabek A. M., Kavlock R. J., Kimmel C. A., Park C., Spitzer H. L. Benchmark dose workshop: Criteria for use of a benchmark dose to estimate a reference dose. Regul. Toxicol. Pharmacol. 21:1995;296-306.
7. Barton H A., Andersen M. E. Endocrine active compounds: From biology to dose response assessment. Crit. Rev. Toxicol. 28:1998;363-423.
8. Branham W. S., Zehr D. R., Sheehan D. M. Differential sensitivity of rat uterine growth and epithelium hypertrophy to estrogens and antiestrogens. Proc. Soc. Exp. Biol. Med. 203:1993;297-303.
9. Clark J. H., Mani S. K. Actions of ovarian steroid hormones. The Physiology of Reproduction. 1994;Raven Press, New York. p. 1011-1059.
10. Clark J. H., Markaverich B. M. The agonistic and antagonistic effects of short acting estrogens: A review. Pharmacol. Ther. 21:1983;429-453.
11. Clark J. H., Peck E. J. Jr. Female Sex Steroids. 1979;Springer-Verlag, New York.
12. Clewell H. J. III, Andersen M. E. Dose, species, and route extrapolation using physiologically based pharmacokinetic models. Pharmacokinetics in Risk Assessment: Drinking Water and Health. 1987;National Academy Press, Washington. p. 159-182.
13. Conolly R. B., Reitz R. H., Clewell H. J., Andersen M. E. Pharmacokinetics, biochemical mechanism and mutation accumulation: A comprehensive model of chemical carcinogenesis. Toxicol. Lett. 43:1988;189-200.
14. Crump K. S. A new method for determining allowable daily intakes. Fundam. Appl. Toxicol. 4:1984;854-871.
15. Crump K. S. Calculation of benchmark doses from continuous data. Risk Anal. 15:1995;79-89.
16. Dohler K. D., Wuttke W. Changes with age in levels of serum gonadotropins, prolactin and gonadal steroids in prepubertal male and female rats. Endocrinology. 97:1975;898-907.
17. Dohler K. D., Wuttke W. Circadian fluctuations of serum hormone levels in prepubertal male and female rats. Acta Endocrinol. 83:1976;269-279.
18. 3. Biochim. Biophys. Acta. 136:1967;498-507.
19. EPA, 1995, The Use of the Benchmark Dose Approach in Health Risk Assessment, U.S. Environmental Protection Agency, Washington, DC.
20. EPA, 1996, Proposed Guidelines for Carcinogen Risk Assessment, Office of Research and Development, Washington, DC.
21. Gaylor D. W., Slikker W. Jr. Risk assessment for neurotoxic effects. Neuro Toxicology. 11:1990;211-218.
22. Grunert G., Porcia M., Tcernitchin A. N. Differential potency of oestradiol-17b and diethylstilboestrol on separate groups of responses in the rat uterus. J. Endocrinol. 110:1986;103-114.
23. Huet Y. M., Dey S. K. Role of early and late oestrogenic effects on implantation in the mouse. J. Reprod. Fertil. 81:1987;453-458.
24. Jensen E. V., Jacobson H. I. Basic guides to the mechanism of estrogen action. Recent Prog. Horm. Res. 18:1962;387-414.
25. Jensen E. V., Jacobson H. I., Flesher J. W., Saha N. N., Gupta G. N., Smith S., Colucci V., Shiplacoff D., Neumann H. G., DeSombre E. R., Jungblut P. W. Estrogen receptors in target tissues. Pincus G., Nakao T., Tait J. F. Steroid Dynamics. 1966;133-157 Academic Press, New York.
26. Kavlock R. J., Allen B. C., Faustman E. M., Kimmel C. A. Dose-response assessments for developmental toxicity. IV. Benchmark doses for fetal weight changes. Fundam. Appl. Toxicol. 26:1995;211-222.
27. Kaye A. M., Sheratzky D., Lindner H. R. Kinetics of DNA synthesis in immature rat uterus: Age dependence and estradiol stimulation. Biochim. Biophys. Acta. 261:1972;475-486.
28. Kerr M. B., Marshall K., Senior J. A comparison of the uterotrophic response in cyclic and ovariectomized normotensive and spontaneously hypertensive rats. J. Endocrinol. 135:1992;263-269.
29. Kneifel M. A., Leytus S. P., Fletcher E., Weber T., Mangel W. F., Katzenellenbogen B. S. Uterine plasminogen activator activity: Modulation by steroid hormones. Endocrinology. 111:1982;493-499.
30. Lan N. C., Katzenellenbogen B. S. Temporal relationships between hormone receptor binding and biological responses in the uterus: Studies with short- and long-acting derivatives of estriol. Endocrinology. 98:1976;220-227.
31. Lobo R. A., Cassidenti D. L. Pharmacokinetics of oral 17 β-estradiol. J. Reprod. Med. 37:1992;77-84.
32. Longcope C., Gorbach S., Goldin B., Woods M., Dwyer J., Warram J. The metabolism of estradiol: Oral compared to intravenous administration. J. Steroid Biochem. 23:1985;1065-1070.
33. Loose-Mitchell D. S., Chiappetta C., Stancel G. M. Estrogen regulation ofc-fos. Mol. Endocrinol. 2:1988;946-951.
34. Markaverich B. M., Roberts R. R., Alejandro M., Clark J. H. The effect of low dose continuous exposure to estradiol on the estrogen receptor (type I) and nuclear type II sites. Endocrinology. 114:1984;814-820.
35. Markaverich B. M., Webb B., Densmore C. L., Gregory R. R. Effects of coumestrol on estrogen receptor function and uterine growth in ovariectomized rats. Environ. Health Perspect. 103:1995;574-581.
36. Medlock K. L., Lyttle C. R., Kelepouris N., Newman E. D., Sheehan D. M. Estradiol down-regulation of the rat uterine estrogen receptor. Proc. Soc. Exp. Biol. Med. 196:1991;293-300.
37. Murphy L. J., Ghahary A. Uterine insulin-like growth factor-1: Regulation of expression and its role in estrogen-induced uterine proliferation. Endocr. Rev. 11:1990;443-453.
38. Murrell J. A., Portier C. J., Morris R. W. Characterizing dose-response. I: Critical assessment of the benchmark dose concept. Risk Anal. 18:1998;13-26.
39. Musgrove E. A., Sutherland R. L. Cell cycle control by steroid hormones. Cancer Biol. 5:1994;381-389.
40. O'Connor J. C., Cook J. C., Craven S. C., Van Pelt C. S., Obourn J. D. Anin vivo. Fundam. Appl. Toxicol. 33:1996;182-195.
41. Odum J., Lefevre P. A., Tittensor S., Paton D., Routledge E. J., Beresford N. A., Sumpter J. P., Ashby J. The rodent uterotrophic assay: Critical protocol features, studies with nonyl phenols, and comparison with a yeast estrogenicity assay. Regul. Toxicol. Pharmacol. 25:1997;176-188.
42. Plowchalk D. R. Physiologically-based modeling of estradiol pharmacokinetics in rats and humans: A tool for studying the dose-response of estradiol. Toxicol. Sci. 42:1998.
43. Reel J. R., Lamb J. C. IV, Neal B. H. Survey and assessment of mammalian estrogen biological assays for hazard characterization. Fundam. Appl. Toxicol. 34:1996;288-305.
44. Sheehan D. M., Branham W. S., Guiterrez-Cernosek R., Cernosek S. F. Jr. Effects of continuous estradiol administration by polydimethylsiloxane and paraffin implants on serum hormone levels and uterine responses. J. Am. Coll. Toxicol. 3:1984;303-316.
45. Sheehan D. M., Branham W. S., Medlock K. L. An estrogen developmental potency and toxicity assay for environmental estrogens. Teratology. 51:1995;196-197.
46. Sheehan D. M., Branham W. S., Medlock K. L., Olson M. E., Zehr D. R. Uterine responses to estradiol in the neonatal rat. Endocrinology. 109:1981;76-81.
47. Shelby M. D., Newbold R. R., Tully D. B., Chae K., Davis V. L. Assessing environmental chemicals for estrogenicity using a combination ofin vitroin vivo. Environ. Health Perspect. 104:1996;1296-1300.
48. Smith M. S., Freeman M. E., Neill J. D. The control of progesterone secretion during the estrous cycle and early pseudopregnancy in the rat: Prolactin, gonadotropin and steroid levels associated with rescue of the corpus luteum of pseudopregnancy. Endocrinology. 92:1975;219-226.
49. Stancel G. M., Boettger-Tong H., Hyder S. M., Kirkland J. L., Loose-Mitchell D. S. Uterinec-fos: Khan S. A., Stancel G. M. Protooncogenes and Growth Factors in Steroid Hormone Induced Growth and Differentiation. 1994;87-104 CRC Press, Boca Raton.
50. Zacharewski T. In vitro. Environ. Sci. Technol. 31:1997;613-623.